RT Journal Article
T1 Clinical Utility of microRNAs in Exhaled Breath Condensate as Biomarkers for Lung Cancer.
A1 Pérez-Sánchez, Carlos
A1 Barbarroja, Nuria
A1 Pantaleão, Lucas C
A1 López-Sánchez, Laura M
A1 Ozanne, Susan E
A1 Jurado-Gámez, Bernabé
A1 Aranda, Enrique
A1 Lopez-Pedrera, Chary
A1 Rodríguez-Ariza, Antonio
K1 biomarkers
K1 exhaled breath condensate
K1 lung cancer
K1 microRNA
K1 personalized medicine
AB This study represents a novel proof of concept of the clinical utility of miRNAs from exhaled breath condensate (EBC) as biomarkers of lung cancer (LC). Genome-wide miRNA profiling and machine learning analysis were performed on EBC from 21 healthy volunteers and 21 LC patients. The levels of 12 miRNAs were significantly altered in EBC from LC patients where a specific signature of miR-4507, miR-6777-5p and miR-451a distinguished these patients with high accuracy. Besides, a distinctive miRNA profile between LC adenocarcinoma and squamous cell carcinoma was observed, where a combined panel of miR-4529-3p, miR-8075 and miR-7704 enabling discrimination between them. EBC levels of miR-6777-5p, 6780a-5p and miR-877-5p predicted clinical outcome at 500 days. Two additional miRNA signatures were also associated with other clinical features such as stage and invasion status. Dysregulated EBC miRNAs showed potential target genes related to LC pathogenesis, including CDKN2B, PTEN, TP53, BCL2, KRAS and EGFR. We conclude that EBC miRNAs might allow the identification, stratification and monitorization of LC, which could lead to the development of precision medicine in this and other respiratory diseases.
SN 2075-4426
YR 2021
FD 2021-02-09
LK https://hdl.handle.net/10668/25814
UL https://hdl.handle.net/10668/25814
LA en
DS RISalud
RD Apr 11, 2025